by Kevin McNerney, MD
Kevin McNerney, MD, is the first author of the article “Management practices of CAR T-cell-related inflammatory toxicities: a survey of pediatric CAR T-cell providers.” He shares in...
by Alex Kadhim
Researchers at McMaster University, collaborating with the Ottawa Hospital Research Institute, have found that a paired vaccine plus CAR strategy can broadly boost adoptively transferred T cells...
by Alex Khadhim
Researchers at University Hospital of Leipzig and Memorial Sloan Kettering Cancer Center have demonstrated that the BCMA CAR T product ciltacabtagene autoleucel appears to deliver deeper and...
by ASTCT Talks
In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD (The University of Texas MD Anderson Cancer Center; Pharmacy SIG Immediate Past-Chair), sits down with Zainab Shahid, MD (Memorial...
by Journal of Clinical Investigation
IFNγ blockade curtails the incidence of high-grade toxicities associated with chimeric antigen receptor (CAR) T-cell therapy, researchers report. Observations from a murine model of toxicities...
by Alex Kadhim
Researchers at the University of Geneva have found that engineering CAR T cells to target Tenascin-C (TNC), an extracellular matrix protein enriched in glioblastoma, can shrink tumors and prolong...